DEST
BADDestiny Pharma to Delist from AIM, Transition to Private Company
Biotech firm Destiny Pharma to delist from AIM, transition to private company structure
DEST
0.00%
Market Cap
Volume
0
NaN% of avg
P/E Ratio
N/A
EPS (TTM)
N/A
Beta
N/A
Day Range
p - p
52 Week Range
N/AppN/Ap
p
No data available for this timeframe
DEST
GOODDestiny Pharma Chairman Increases Stake
Biotech firm Destiny Pharma sees Chairman increase stake, signaling confidence in the company's future.
DEST
GOODDestiny Pharma's XF-73 Prevents Sepsis in Burn Wound Infection Study
Promising preclinical results for biotech company's infection-fighting drug
DEST
GOODDestiny Pharma's XF-73 Nasal Gel Reduces Need for Post-Surgical Antibiotics
Positive news for this biotech company's lead drug candidate, which could help reduce post-surgical antibiotic use.
DEST
BADDestiny Pharma Proposes AIM Delisting and Private Company Transition
Biotech company Destiny Pharma proposes delisting from AIM and transitioning to private status, citing challenges in securing funding for late-stage drug trials.
DEST
NEUTRALDestiny Pharma Issues Shares on Option Exercise
Biotech issues new shares on option exercise
DEST
GOODDestiny Pharma Unveils Promising Anti-Fungal Compound XF-70
Promising anti-fungal data from biotech company's novel drug candidate
DEST
NEUTRALDestiny Pharma Evaluates Strategic Options Amid Cash Runway Concerns
Biotech company evaluates strategic options amid funding concerns for lead drug candidate
DEST
GOODDestiny Pharma's XF-73 Nasal Granted Innovative Pathway by UK Regulator
Innovative biotech company secures regulatory support for lead drug candidate targeting post-surgical infections
DEST
NEUTRALDestiny Pharma Issues New Shares Following Option Exercise
Biotechnology company Destiny Pharma issues new shares following option exercise